<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vos JR</submitter><funding>NCI NIH HHS</funding><pagination>2553-62</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4979233</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>33(23)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Recommendations for treating patients who carry a BRCA1/2 gene are mainly based on cumulative lifetime risks (CLTRs) of breast cancer determined from retrospective cohorts. These risks vary widely (27% to 88%), and it is important to understand why. We analyzed the effects of methods of risk estimation and bias correction and of population factors on CLTRs in this retrospective clinical cohort of BRCA1/2 carriers.&lt;h4>Patients and methods&lt;/h4>The following methods to estimate the breast cancer risk of BRCA1/2 carriers were identified from the literature: Kaplan-Meier, frailty, and modified segregation analyses with bias correction consisting of including or excluding index patients combined with including or excluding first-degree relatives (FDRs) or different conditional li</pubmed_abstract><journal>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</journal><pubmed_title>Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.</pubmed_title><pmcid>PMC4979233</pmcid><funding_grant_id>P01 CA053996</funding_grant_id><pubmed_authors>Oosterwijk JC</pubmed_authors><pubmed_authors>Malone KE</pubmed_authors><pubmed_authors>de Bock GH</pubmed_authors><pubmed_authors>Mourits MJ</pubmed_authors><pubmed_authors>Brohet RM</pubmed_authors><pubmed_authors>Hsu L</pubmed_authors><pubmed_authors>de Vries J</pubmed_authors><pubmed_authors>Vos JR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.</name><description>&lt;h4>Purpose&lt;/h4>Recommendations for treating patients who carry a BRCA1/2 gene are mainly based on cumulative lifetime risks (CLTRs) of breast cancer determined from retrospective cohorts. These risks vary widely (27% to 88%), and it is important to understand why. We analyzed the effects of methods of risk estimation and bias correction and of population factors on CLTRs in this retrospective clinical cohort of BRCA1/2 carriers.&lt;h4>Patients and methods&lt;/h4>The following methods to estimate the breast cancer risk of BRCA1/2 carriers were identified from the literature: Kaplan-Meier, frailty, and modified segregation analyses with bias correction consisting of including or excluding index patients combined with including or excluding first-degree relatives (FDRs) or different conditional li</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Aug</publication><modification>2025-04-21T19:02:07.432Z</modification><creation>2019-03-27T02:20:16Z</creation></dates><accession>S-EPMC4979233</accession><cross_references><pubmed>26150446</pubmed><doi>10.1200/jco.2014.59.0463</doi><doi>10.1200/JCO.2014.59.0463</doi></cross_references></HashMap>